Evidence map›Paper›PMID 30561888›Full record

ArticleHIV medicine2019

Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naïve youth in the HIV Research Network.

D C Griffith, C Farmer, K A Gebo, S A Berry, J Aberg, R D Moore, A H Gaur, W C Mathews, R Beil, P T Korthuis and 4 more

Open access · bronzeAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in HIV medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

D C GriffithJohns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-3818-4226
C FarmerJohns Hopkins University School of Medicine, Baltimore, MD, USA.
K A GeboJohns Hopkins University School of Medicine, Baltimore, MD, USA.
S A BerryJohns Hopkins University School of Medicine, Baltimore, MD, USA.
J AbergMount Sinai School of Medicine, New York, NY, USA.
R D MooreJohns Hopkins University School of Medicine, Baltimore, MD, USA.
A H GaurSt. Jude's Children's Research Hospital, Memphis, TN, USA.
W C MathewsUniversity of California at San Diego, San Diego, CA, USA.
R BeilMontefiore Medical Group, New York, NY, USA.
P T KorthuisOregon Health & Sciences University, Portland, OR, USA.
A E NijhawanUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.
R M RutsteinChildren's Hospital of Philadelphia, Philadelphia, PA, USA.
A L AgwuJohns Hopkins University School of Medicine, Baltimore, MD, USA.
HIV Research Network
Johns Hopkins University · USChildren's Hospital of Philadelphia · USIcahn School of Medicine at Mount Sinai · USMontefiore Medical Center · USOregon Health & Science University · USSt. Jude Children's Research Hospital · USThe University of Texas Southwestern Medical Center · USUniversity of California San Diego · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
University of California, San Diego Clinical Trial UnitUM1AI069536 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STEPHEN A SPECTOR · 2012 to 2026
$34.0M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Research Training in Pediatric Infectious DiseasesT32AI052071 · NIAID · JOHNS HOPKINS UNIVERSITY · PI AARON M MILSTONE · 2002 to 2026
$5.2M
Agency for Healthcare Research and Quality HHSA290201100007CCenter for AIDS Research, University of California, San Diego AI036214HRSA HHS HHSH250201600009CNIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI094189NIAID NIH HHS T32 AI052071NIAID NIH HHS UM1 AI069536NIDA NIH HHS U01 DA036935NIH HHS T32AI052071
6 · The paper itself

Abstract

objectivesSeveral single-tablet regimens (STRs) are now available and are recommended for first-line antiretroviral therapy (ART); however, STR use for youth with HIV (YHIV) has not been systematically studied. We examined the characteristics associated with initiation of STRs versus multi-tablet regimens (MTRs) and the virological outcomes for youth with nonperinatally acquired HIV (nPHIV).

methodsA retrospective cohort study of nPHIV youth aged 13-24 years initiating ART between 2006 and 2014 at 18 US HIV clinical sites in the HIV Research Network was performed. The outcomes measured were initiation of STRs versus MTRs, virological suppression (VS) at 12 months, and time to VS. Demographic and clinical factors associated with initiation of STR versus MTR ART and VS (< 400 HIV-1 RNA copies/mL) at 12 months after initiation were assessed using multivariable logistic regression. Cox proportional hazards regression was used to assess VS within the first year.

resultsOf 987 youth, 67% initiated STRs. Of the 589 who had viral load data at 1 year, 84% of those on STRs versus 67% of those on MTRs achieved VS (P < 0.01). VS was associated with STR use [adjusted odds ratio (AOR) 1.61; 95% confidence interval (CI) 1.01-2.58], white (AOR 2.41; 95% CI 1.13-5.13) or Hispanic (AOR 2.38; 95% CI 1.32-4.27) race/ethnicity, and baseline CD4 count 351-500 cells/μL (AOR 1.94; 95% CI 1.18-3.19) and > 500 cells/μL (AOR 1.76; 95% CI 1.0-3.10). STR use was not associated with a shorter time to VS compared with MTR use [hazard ratio (HR) 1.07; 95% CI 0.90-1.28].

conclusionsUse of STR was associated with a greater likelihood of sustained VS 12 months after ART initiation in YHIV.

Indexed as

AdolescentAnti-Retroviral AgentsFemaleHIV-1HIV InfectionsHumansLogistic ModelsMaleRetrospective StudiesTabletsTreatment Adherence and ComplianceViral LoadYoung AdultAnti-Retroviral AgentsTabletsadherenceantiretroviral therapyHIVsingle tabletyouth

Identifiers

PMID30561888
PMCPMC6498847
OpenAlexW2905016029

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.